Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2.

"the data underlying this article are available in arrayexpress (accession e-mtab-11349)."

"Conflict of Interest JKN reports personal fees from Norsa Pharma, a grant from Biocodex Microbiota Foundation, and non-financial support from Nutricia outside of the submitted work. RK has served as a speaker for Ferring and has received support for research from IBD-Character [EU FP7 2858546]. DB has received personal fees as speaker and/or advisory board member for Ferring, Janssen, Pfizer, and Takeda. JW reports personal fees and non-financial support from Biocodex, BGP Products, Chiesi, Hipp, Humana, Mead Johnson Nutrition, Merck Sharp & Dohme, Nestle, Norsa Pharma, Nutricia, Roche, Sequoia Pharmaceuticals, and Vitis Pharma, outside of the submitted work, and also grants, personal fees, and non-financial support from Nutricia Research Foundation Poland, also outside of the submitted work. JJH has received personal fees as speaker, consultant, and/or advisory board member for AbbVie, Aqilion AB, Celgene, Celltrion, Dr Falk Pharma and the Falk Foundation, Ferring, Hospira, Janssen, MEDA, Medivir, MSD, Olink Proteomics, Pfizer, Prometheus Laboratories, Sandoz/Novartis, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, UCB, and has received grant support from Janssen, MSD, and Takeda, outside of the submitted work. JS has served as a speaker, a consultant, and an advisory board member for MSD, Ferring, Abbvie, and Shire, a consultant with Takeda, has received speaking fees from MSD, travel support from Shire, and has received research funding from Abbvie, Wellcome, CSO, MRC, and the EC grant IBDBIOM."

"Funding This work was supported by the European Union’s Seventh Framework Programme [FP7] grant IBD Character [2858546] and the Polish National Science Centre [2017/25/B/NZ5/02783 to JW]."